Skip to content

Remainder of 2026 at other companies

Ginkgo Bioworks logo
Ginkgo BioworksDNA
UCT
Ultra Clean HoldingsUCTT

Other financials

Income statement

See full
Revenue$71.4M-7.5%
Gross profit$21.2M-11.6%
Operating income$5.2M-38.6%
Net income$3.4M-30.1%
EPS (diluted)$1.13-30.7%

Balance sheet

See full
Cash & equivalents$10.0M-42.0%
Total debt$25.3M+6.6%
Total equity$74.7M+15.9%
Total assets$178.3M-8.4%

Cash flow

See full
Operating cash flow$5.5M-42.0%
CapEx$928.0K+79.8%
Free cash flow$4.5M-49.0%

Valuation

See full
Market cap$101.96M-34.8%
Enterprise value$117.3M-28.0%
P/E10.6×-3.1×
P/S0.4×-0.3×

Profitability

See full
Gross margin28.5%-0.1pp
Operating margin5.9%-1.5pp
Net margin3.4%-1.3pp
FCF margin5.2%

Returns & leverage

See full
Return on equity13.8%-5.3pp
Debt / equity0.3×0.0×
Current ratio2.2×0.0×

Where this comes from

Reported directly by Kewaunee Scientific Corporation in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: Kewaunee Scientific Corporation’s 10-Q, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kewaunee Scientific Corporation's remainder of 2026.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kewaunee Scientific Corporation's remainder of 2026?
Kewaunee Scientific Corporation (KEQU) reported remainder of 2026 of $385K in Q4 2025.